In active UC, upadacitinib induced and maintained remission

Geoffrey M Forbes

doi:10.7326/J22-0073

In active UC, upadacitinib induced and maintained remission

Ann Intern Med. 2022 Oct;175(10):JC113. doi: 10.7326/J22-0073. Epub 2022 Oct 4.

Author

Geoffrey M Forbes¹

Affiliation

¹ University of Western Australia, Perth, Western Australia, Australia (G.M.F.).

PMID: 36191310
DOI: 10.7326/J22-0073

Abstract

Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113-28. 35644166.

Publication types

Randomized Controlled Trial
Comment

MeSH terms

Colitis, Ulcerative* / drug therapy
Double-Blind Method
Heterocyclic Compounds, 3-Ring
Humans
Remission Induction
Treatment Outcome

Substances

Heterocyclic Compounds, 3-Ring
upadacitinib